Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > February 17, 2020
Daily News
February 17, 2020
- Dovobet Foam Formulation Filed in Japan: LEO Pharma/Kyowa Kirin
February 17, 2020
- Japan OKs Edirol Generics towards June Listing, First Gx Entries for 13 Other Drugs Too
February 17, 2020
- Tecentriq-Avastin Combo Filed for HCC in Japan: Chugai
February 17, 2020
- Otsuka’s Pharma Sales Surge as Tolvaptan Grows Six-Fold in North America
February 17, 2020
- Zolgensma Up for Japan Advisory Panel Meeting on Feb. 26, Listing Expected as Early as May
February 17, 2020
- Teijin Pharma Set to Boost Partnerships in R&D, Seeking Licensee for Diabetic Nephropathy Drug: President
February 17, 2020
- Eisai Pulls Belviq from US Market after FDA Flags Cancer Risks
February 17, 2020
- Chugai, US Foundation Medicine Team Up with NCC for Blood-Based Genomic Testing
February 17, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…